Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP +4.71%36 EV-to-EBITDA is 29.11 as of Aug. 15, 2026, which is 406% above its 10-year median of 5.75. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,644 Consumer Packaged Goods companies, Integrated Biopharma ranks worse than 86.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Integrated Biopharma's enterprise value is $2.74 Mil.
Integrated Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.09 Mil. Therefore, Integrated Biopharma's EV-to-EBITDA for today is 29.11.
The historical rank and industry rank for Integrated Biopharma's EV-to-EBITDA or its related term are showing as below:
INBP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.47 Med: 5.75 Max: 66.34
Current: 29.12
During the past 13 years, the highest EV-to-EBITDA of Integrated Biopharma was 66.34. The lowest was 1.47. And the median was 5.75.
INBP's EV-to-EBITDA is ranked worse than 86.07% of 1644
companies
in the Consumer Packaged Goods industry
Industry Median: 9.115
vs INBP: 29.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Integrated Biopharma's PE Ratio (TTM) for today is calculated as:
Integrated Biopharma's share price for today is $0.16795.
Integrated Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Integrated Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Integrated Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's EV-to-EBITDA falls into.
Integrated Biopharma's current Enterprise Value is $2.74 Mil.
Integrated Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (INBP) has a EV-to-EBITDA of 29.11 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Integrated Biopharma. This is 406% above median its historical median of 5.75. Over the past decade, Integrated Biopharma's EV-to-EBITDA has ranged from 1.47 to 66.34. According to the industry distribution chart, Integrated Biopharma ranks #1415 out of 1644 companies in the Consumer Packaged Goods industry, placing it in the top 86.1%.
Is Integrated Biopharma's EV-to-EBITDA too high?
Integrated Biopharma's current EV-to-EBITDA of 29.11 is 406% above median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 66.34. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.12. Integrated Biopharma's value of 29.11 is 219.4% above this industry median. Based on the distribution chart, Integrated Biopharma ranks #1415 out of 1644 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's EV-to-EBITDA compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #1415 out of 1644 companies for EV-to-EBITDA. This places Integrated Biopharma in the lower half of its industry. The industry median EV-to-EBITDA is 9.12. Integrated Biopharma's value of 29.11 is 219.4% above this benchmark. Historically, Integrated Biopharma's own EV-to-EBITDA has ranged from 1.47 to 66.34 over the past decade. While the company's 10-year median is 5.75 vs. the industry median of 9.12, Integrated Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.12, based on 1,644 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Biopharma's current EV-to-EBITDA of 29.11 is 219.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Integrated Biopharma. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current EV-to-EBITDA is 29.11, which is 406% above median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.4% below its estimated fair value. The current EV-to-EBITDA is 29.11, which is 406% above median its 10-year median of 5.75 and 219.4% above the Consumer Packaged Goods industry median of 9.12. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current EV-to-EBITDA is 29.11 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.17 is trading 35.4% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
EV-to-EBITDA: 29.11 (406% above median its 10-year median of 5.75)
GF Value™: $0.26 vs. price of $0.17 (35.4% below fair value)
Industry Position: 219.4% above the Consumer Packaged Goods median (#1415 of 1644)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
